

General medical comorbidities in Brazilian outpatients with bipolar disorder type I

Comorbidades médicas em pacientes ambulatoriais com transtorno do humor bipolar tipo I

CAMILA LUZIA ROGANTI LEITE MOREIRA¹, ELISA BRIETZKE¹, BENY LAFER¹

¹ Programa de Transtorno Bipolar (PROMAN), Instituto de Psiquiatria, Universidade de São Paulo (USP), Brasil.

Received: 25/2/2011 – Accepted: 5/8/2011

Abstract

Background: Bipolar disorder (BD) has been associated with high rates of general medical comorbidities (GMC) and medical risk factors. There have been scarce reports about this prevalence in Brazilian subjects with BD. **Objective:** Describe the prevalence of GMC in a sample of BD type I patients. **Methods:** Clinical records of 195 patients with BD type I were reviewed for identification of GMC. Patients with and without GMC were compared using the Mann-Whitney nonparametric test and the chi-Square test. **Results:** Sixty-three percent of patients had at least one medical comorbidity. The most prevalent conditions were: migraine (31.8%), hypothyroidism (24.1%), hypertension (11.3%), traumatic brain injuries (10.3%), asthma (9.7%), epilepsy (8.2%), diabetes (5.1%), stroke (2.1%) and hyperthyroidism (1%). Age and duration of illness were positively associated with the presence of GMC ($p < 0.001$). **Discussion:** In our study, in accordance with previous reports, the majority of patients presented at least one general medical disorder. The principal limitation of this study is the fact that diagnose of GMC was made based on self-report. There are scarce studies addressing GMC in the Brazilian population with BD and this report can contribute to improve diagnostic vigilance, assessment, treatment planning and decrease the burden associated with BD.

Moreira CLRL, et al. / *Rev Psiq Clín.* 2011;38(6):227-30

Keywords: Bipolar disorder, general medical comorbidity, migraine.

Resumo

Contexto: O transtorno do humor bipolar (THB) está associado a altas taxas de comorbidades médicas gerais (CMGs) e fatores de risco para problemas médicos, porém há escassos relatos sobre a prevalência dessas condições em brasileiros com THB. **Objetivo:** Descrever a prevalência de CMGs em uma amostra de pacientes com THB tipo I. **Métodos:** Dados clínicos de 195 pacientes com THB tipo I foram revisados para identificação de CMGs. Pacientes com e sem CMGs foram comparados usando o teste não paramétrico Mann-Whitney e o teste qui-quadrado. **Resultados:** Sessenta e três por cento dos pacientes relataram pelo menos uma comorbidade médica. As condições mais prevalentes foram: enxaqueca (31,8%), hipotireoidismo (24,1%), hipertensão (11,3%), traumatismo craniano (10,3%), asma (9,7%), epilepsia (8,2%), diabetes (5,1%), acidente vascular cerebral (2,1%) e hipertireoidismo (1%). Idade e duração da doença foram positivamente associadas à presença de CMGs ($p < 0,001$). **Conclusão:** Em concordância com relatos prévios, a maioria dos pacientes apresentou pelo menos uma doença médica. A principal limitação deste estudo reside no fato de o diagnóstico de CMGs ter sido baseado no autorrelato. Há escassos estudos visando à identificação de comorbidades médicas na população brasileira com THB e este estudo pode contribuir para melhor vigilância diagnóstica, avaliação, tratamento e diminuição da sobrecarga associada ao THB.

Moreira CLRL, et al. / *Rev Psiq Clín.* 2011;38(6):227-30

Palavras-chave: Transtorno bipolar, comorbidades médicas, enxaqueca.

Introduction

Bipolar disorder (BD) is a recurrent and chronic mental illness with lifetime prevalence rates estimated to be 3%-6% in the general population¹. The disorder is characterized by mood episodes alternating with euthymic periods², and it is associated with functional decline^{3,4}, higher mortality rates and significant health care costs³. Comorbidities, high risk of suicide, social and professional impairment and low adherence to treatment increase the burden and cost of illness and worsen the prognosis⁵.

Presence of one or more additional psychiatric disorders is the rule rather than the exception for BD. Data from the Stanley Foundation Bipolar Network indicate that 65% of patients with BD also have at least one comorbid lifetime axis I disorder and almost a quarter of these patients have three or more diagnoses⁶. In addition to their psychiatric illness, bipolar patients experience certain general medical comorbidities (GMC) at a higher rate than the general public. Compared with the general population, BD patients have a prevalence of diabetes mellitus approximately three times higher

(9.9% versus 3.4%)⁷, a prevalence of migraine more than two times higher (24.8% versus 10.3%)⁸, and the mortality ratio of BD patients for cardiovascular disease is 3.0¹. In the United States and Canada the lifetime prevalence of at least one medical disease varies from 7.2% to 64.3%⁸⁻¹².

Some of this excess morbidity has been associated with adverse effects of medications used to treat BD and also with lifestyle patterns, as is the case for obesity, diabetes, and hypothyroidism^{7,13,14}. However, in most cases, the etiology of the comorbidity is not fully understood, as it is unclear whether a medical disorder is truly comorbid, is a consequence of treatment, or a combination of both¹⁵.

Medical risk factors and GMC affect the course and the severity of BD as well as its treatment^{2,16,17}, and their impact is significant due to reasons including quality of life, delivery of psychiatry and medical services, mortality¹⁰ and disability¹⁸.

Individuals suffering from BD may be particularly at risk for obesity, a strong predictor of major medical problems including hypertension, cardiovascular disease, and diabetes mellitus, and

the prevalence of this condition has been estimated between 8.3%-49%^{13,16,17,19-23}. Obese bipolar patients experience a greater number of lifetime depressive and manic episodes, more severe and difficult-to-treat index affective episode¹⁶, and are more likely to report a lifetime history of suicide attempts¹⁷.

A cross-sectional study found that having a chronic medical disease was associated with less successful employment outcomes, greater dependency on others for assistance, more mental health hospitalizations, more mental health consultations, and more use of psychotropic medications in patients with BD⁸. Additionally, another research showed that GMC was associated with a worse quality of life especially in its physical domain⁹.

Although several studies have shown a high prevalence of GMC in BD, there have been scarce reports about the prevalence of these conditions in Brazilian subjects with BD. The aim of the present study is to evaluate the prevalence of GMC in a sample of Brazilian outpatients with BD.

Methods

The study was carried out at the Bipolar Disorder Research Program at the Institute of Psychiatry of the University of São Paulo Medical School. It was approved by the Institute's ethics committee and written informed consent was obtained from all subjects participating in the study. One hundred and ninety five outpatients with bipolar disorder type I (age ≥ 18 years old) were evaluated. All subjects were diagnosed according to the DSM-IV criteria using the Structured Clinical Interview for DSM-IV (SCID-P). Sociodemographic and clinical variables were reviewed and GMC was evaluated by a self-report questionnaire. This questionnaire assessed epilepsy, history of traumatic brain injuries, migraine, asthma, diabetes, hypothyroidism, hyperthyroidism, hypertension, and stroke and was administered during the patient's baseline evaluation. According to the answers the sample was divided in two groups: subjects who had at least one GMC and subjects who did not.

The statistical analysis was performed using the Statistical Package for the Social Sciences, version 14 (SPSS Inc., Chicago, IL, USA). The variables age; number of manic, depressive, mixed and total episodes; number of hospitalizations; number of suicide attempts and duration of illness were compared between the groups using Mann-Whitney nonparametric test. We also compared the variables gender, marital status and ethnicity using chi-square test. The level of statistical significance was set at $\alpha = 0.05$.

Results

The sociodemographic and clinical characteristics of the study sample are shown in table 1. Based on the overall sample the mean age was 39.2 years old (SD = 10.9), more than half were female (69.7%) and 42.6% were married. The largest ethnic group was Caucasian (75.4%), followed by Afro-American (22.5%), Asian (1.5%) and others (0.5%). The median number of total episodes was 7 (IR=9) and the mean duration of illness was 16.4 years (SD = 10.7). Nearly sixty-nine percent of the subjects had at least one GMC and the most prevalent conditions were: migraine (31.8%), hypothyroidism (24.1%), hypertension (11.3%), history of traumatic brain injuries (10.3%), asthma (9.7%), epilepsy (8.2%), diabetes (5.1%), stroke (2.1%), hyperthyroidism (1.0%) (Table 2). Twenty three percent of the sample had two or more GMC and 4.1% had 3 or more GMC. Age and duration of illness were positively associated with the presence of GMC ($p < 0.001$). No relationship was found between the presence of GMC and gender, marital status, ethnicity, number of episodes (manic, depressive, mixed and total), number of hospitalizations and number of suicide attempts. In order to correct for possible bias in the retrospective assessment of number of episodes, we divided the sample according to the median of total episodes and did not find any difference between the two groups on the presence of GMC.

Table 1. Clinical and demographic characteristics of the subjects

Variables	
Age in years, mean (SD)	39.2 (10.9)
Gender (female)	69.7%
Marital status	
Married	42.6%
Single	39.5%
separated, divorced or widow	17.9%
Ethnicity	
Caucasian	75.4%
Afro-American	22.5%
Asian	1.5%
Other	0.5%
Number of total episodes, median (IR)*	7 (9)
Number of manic episodes, median (IR)	3 (3)
Number of depressive episodes, median (IR)	3 (5)
Number of mixed episodes, median (IR)	0 (0)
Number of hospitalizations, median (IR)	1 (2)
Number of suicide attempts, median (IR)	0 (2)
Duration of illness in years, mean (SD)	16.4 (10.7)

* Underestimated number (some subjects reported a number of episodes as "too numerous to count").

IR: interquartile range.

Table 2. Prevalence of GMC in subjects with BD (n = 195)

General medical comorbidity	N	%
Migraine	62	31.8
Hypothyroidism	47	24.1
Hypertension	22	11.3
History of traumatic brain injuries	20	10.3
Asthma	19	9.7
Epilepsy	16	8.2
Diabetes	10	5.1
Stroke	4	2.1
Hyperthyroidism	2	1.0

Discussion

Our findings are similar to prior studies in other populations pointing to an alarmingly higher prevalence of GMC among patients with BD when compared to the general population. In accordance with previous reports, the majority of subjects studied presented at least one concomitant medical disorder. The duration of illness was positively associated with the presence of GMC ($p < 0.001$) and it is in conformance with the findings of Soreca *et al.*²⁴, which described that medical burden was related to it.

Surprisingly, in our study, almost 32% of BD outpatients had migraine. We found in the literature a well-established association between migraine and depression, but among the BD population it has been indicated that BD II may co-exist with migraine more often than BD I²⁵⁻²⁸. It has been reported by other groups that these co-occurring diseases are associated with greater dysfunction, an increased risk of suicidal behaviour and comorbid anxiety disorders^{8,25}. As migraine is associated with the female gender and we have a higher percentage of women in the sample, it is possible that migraine prevalence may be, in fact, an artifact of the unequal distribution of gender. Notwithstanding is known that bipolar women are more likely to suffer from migraine than men^{8,29,30}. In addition, the use of a self-report instrument to determine the presence of migraine might overestimate the rate of migraine occurrence.

The second most prevalent condition was hypothyroidism (24.1%), and it may be related to the disease itself or to the medications used by these patients³¹. A recent study indicated that lithium, carbamazepine, and valproate might increase the risk of hypothyroidism, particularly if used together¹⁴. In our sample 72.3% of the patients had been using at least one of these three medications during the last year, which could potentially explain the high rate of this illness.

Excess cardiovascular mortality in BD has been documented for several years and hypertension, an important risk factor, is among the most common medical conditions and is a major contributor to increased treatment costs in BD³²⁻³⁴. In the present study, 11.3% of BD I subjects reported being diagnosed with arterial hypertension, although previous estimates for hypertension prevalence in BD patients were generally from 15 to 39%^{17,33,35}.

One of the limitations of the present study is that our results are based on an assessment by a self-report questionnaire of the patient's diagnosed GMC and in addition no standardized evaluation was applied to assess these illnesses.

Despite its limitations, there are scarce studies addressing GMC in the Brazilian population with BD and this report can contribute to improve diagnostic vigilance and helps clinicians tailor treatment strategies.

Our findings suggest the need for future studies addressing GMC and BD comorbidities and the necessity to optimize care and achieve the best possible treatment outcomes by integrating psychiatric and general medical care. Perhaps most importantly, preventive strategies are needed to reduce the excessive prevalence and impact of general medical disorder among people with BD.

In conclusion, Brazilian outpatients with BD type I have significant rates of GMC and medical risk factors. This report contributes to the knowledge in the field, and our findings support the need for future studies addressing these co-occurring diseases. Additionally, integrated care and the development of diverse therapeutic options, such as group therapy³⁶, diagnostic vigilance and comprehensive treatment are required and could be effective strategies.

Referências

- Goodwin FK, Jamison KR (ed.). Manic-depressive illness: bipolar disorders and recurrent depression. 2nd ed. New York: Oxford University Press; 2007. p. 162-75, 240-5.
- American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington: American Psychiatry Press; 2000. p. 377-91.
- Bauer MS, Kirk G, Gavin C, Williford W. Determinants of functional outcome and healthcare costs in bipolar disorder: a high-intensity follow-up study. *J Affect Disord.* 2001;65:231-41.
- Rea MM, Miklowitz DJ, Thompson MC, Goldstein MJ, Hwang S, Mintz J. Family-focused treatment versus individual treatment of bipolar disorder: results of a randomized clinical trial. *J Consult Clin Psychol.* 2003;71:482-92.
- Costa AMN. Transtorno afetivo bipolar – carga da doença e custos relacionados. *Rev Psiq Clín.* 2008;35:104-10.
- McElroy SL, Altshuler LL, Suppes T, Keck PE, Frye MA, Denicoff KD, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. *Am J Psychiatry.* 2001;158:420-6.
- Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. *Am J Psychiatry.* 1999;156:1417-20.
- McIntyre RS, Konarski JZ, Soczynska JK, Wilkins K, Panjwani G, Bouffard B, et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. *Psychiatr Serv.* 2006;57:1140-4.
- Fenn HH, Bauer MS, Altshuler L, Evans DR, Williford WO, Kilbourne AM, et al. Medical comorbidity and health-related quality of life in bipolar disorder across the adult age span. *J Affect Disord.* 2005;86:47-60.
- Carney CP, Jones LE. Medical comorbidity in women and men with bipolar disorders: a population-based controlled study. *Psychosom Med.* 2006;68:684-91.
- Beyer J, Kuchibhatla M, Gersing K, Krishnan KR. Medical comorbidity in a bipolar outpatient clinical population. *Neuropsychopharmacology.* 2005;30:401-4.
- Perron BE, Howard MO, Nienhuis JK, Bauer MS, Woodward AT, Kilbourne AM. Prevalence and burden of general medical conditions among adults with bipolar I disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry.* 2009;70:1407-15.
- McElroy SL, Frye MA, Suppes T, Dhavale D, Keck PE Jr, Leverich GS, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. *J Clin Psychiatry.* 2002;63:207-13.
- Gau CS, Chang CJ, Tsai FJ, Chao PF, Gau SS. Association between mood stabilizers and hypothyroidism in patients with bipolar disorders: a nested, matched case-control study. *Bipolar Disord.* 2010;12:253-63.
- Krishnan KR. Psychiatric and medical comorbidities of bipolar disorder. *Psychosom Med.* 2005;67:1-8.
- Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. *Am J Psychiatry.* 2003;160:112-7.
- Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. *Bipolar Disord.* 2005;7:424-30.
- Hajek T, Slaney C, Garnham J, Ruzickova M, Passmore M, Alda M. Clinical correlates of current level of functioning in primary care treated bipolar patients. *Bipolar Disord.* 2005;7:286-91.
- Van Winkel R, De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. *Bipolar Disord.* 2008;10:342-8.
- Kim B, Kim S, McIntyre RS, Park HJ, Kim SY, Joo YH. Correlates of metabolic abnormalities in bipolar I disorder at initiation of acute phase treatment. *Psychiatry Investig.* 2009;6:78-84.
- Sicras A, Rejas J, Navarro R, Serrat J, Blanca M. Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database. *Bipolar Disord.* 2008;10:607-16.
- Almeida KM, Macedo-Soares MB, Isler CK, Amaral JA, Caetano SC, Dias RS, et al. Obesity and metabolic syndrome in Brazilian patients with bipolar disorder. *Acta Neuropsychiatrica.* 2009;2:84-8.
- Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, Miller DD, Haynes WG. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. *Ann Clin Psychiatry.* 2008;20:131-7.
- Soreca I, Fagiolini A, Frank E, Houck PR, Thompson WK, Kupfer DJ. Relationship of general medical burden, duration of illness and age in patients with bipolar I disorder. *J Psychiatr Res.* 2008;42:956-61.
- Ortiz A, Cervantes P, Zlotnik G, Van de Velde C, Slaney C, Garnham J, et al. Cross-prevalence of migraine and bipolar disorder. *Bipolar Disord.* 2010;12:397-403.
- Fasmer OB, Odgaard KJ. Clinical characteristics of patients with major affective disorders and comorbid migraine. *World J Biol Psychiatry.* 2001;2:149-55.
- Low NC, Du Fort GG, Cervantes P. Prevalence, clinical correlates, and treatment of migraine in bipolar disorder. *Headache.* 2003;43:940-9.
- Fasmer OB. The prevalence of migraine in patients with bipolar and unipolar affective disorders. *Cephalalgia.* 2001;21:894-9.
- Blehar MC, DePaulo JR Jr, Gershon ES, Reich T, Simpson SG, Nurnberger JI Jr. Women with bipolar disorder: findings from the NIMH Genetics Initiative sample. *Psychopharmacol Bull.* 1998;34:239-43.
- Calabrese JR, Hirschfeld RM, Reed M, Davies MA, Frye MA, Keck PE, et al. Impact of bipolar disorder on a U.S. community sample. *J Clin Psychiatry.* 2003;64:425-32.
- Valle J, Ayuso-Gutierrez JL, Abril A, Ayuso-Mateos JL. Evaluation of thyroid function in lithium-naive bipolar patients. *Eur Psychiatry.* 1999;14:341-5.
- Osby U, Brandt L, Correia N, Ekblom A, Sparén P. Excess mortality in bipolar and unipolar disorder in Sweden. *Arch Gen Psychiatry.* 2001;58:844-50.
- Kilbourne AM, Cornelius JR, Han X, Pincus HA, Shad M, Salloum I, et al. Burden of general medical conditions among individuals with bipolar disorder. *Bipolar Disord.* 2004;6:368-73.
- Guo JJ, Keck PE, Li H, Patel NC. Treatment costs related to bipolar disorder and comorbid conditions among Medicaid patients with bipolar disorder. *Psychiatr Serv.* 2007;58:1073-8.

35. Klumpers UM, Boom K, Janssen FM, Tullen JH, Loonen AJ. Cardiovascular risk factors in outpatients with bipolar disorder. *Pharmacopsychiatry*. 2004;37:211-6.
36. Gomes BC, Lafer B. Psicoterapia em grupo de pacientes com transtorno afetivo bipolar. *Rev Psiq Clín*. 2007;34:84-9.